Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2015-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
2015年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "嘉事堂药业股份有限公司 2015 年半年度财务报告" which translates to "Jia Shi Tang Pharmaceutical Co., Ltd. 2015 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2015. The document is approximately 15,000 characters long and includes substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the content is comprehensive financial reporting for a half-year period. H1 2015
2015-08-25 Chinese
独立董事候选人声明（吴剑）
Regulatory Filings Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Jia Shi Tang Pharmaceutical Co., Ltd., affirming compliance with various legal and regulatory requirements for independent directors. It includes statements about independence, qualifications, and adherence to regulatory rules, but does not contain financial data, earnings, or report summaries. It is not a financial report, earnings release, or management discussion. It is a regulatory compliance declaration related to board/management information but does not announce a change in board or management personnel. It is best classified as a Regulatory Filing (RNS) because it is a formal regulatory disclosure that does not fit into other specific categories like MANG or DIRS.
2015-08-25 Chinese
关于修改公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the modification of the company's articles of association (company bylaws). It details changes approved by the board of directors and mentions that the proposal will be submitted to the shareholders' meeting for approval. The document does not contain financial statements, audit information, or detailed management reports. It is a regulatory announcement about governance changes, specifically about the company's internal rules (articles of association). This fits best under Governance Information (CGR). The document length is short and it is not a report publication announcement or a certification. Therefore, the classification is Governance Information (CGR).
2015-08-25 Chinese
独立董事关于第四届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 嘉事堂药业股份有限公司 regarding several board matters, including the election of non-independent and independent directors, review of related party transactions, and appointment of senior management. It references compliance with company law, stock exchange rules, and company articles. The document is not a full annual or interim report, nor is it a simple announcement. It is a formal independent directors' opinion on board meeting agenda items, which fits best under Board/Management Information (MANG) as it relates to board and senior management changes and opinions. The document length is 2106 characters, indicating it is a detailed opinion rather than a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2015-08-25 Chinese
关于第四届监事会第十六次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 嘉事堂药业股份有限公司 regarding the resolutions of the 16th meeting of the 4th Supervisory Board held on August 25, 2015. It includes details about the election of shareholder representative supervisors, amendments to the company's articles of association, and importantly, the approval of the company's 2015 semi-annual report and its summary. The document states that the Supervisory Board has reviewed and believes the 2015 semi-annual report complies with legal and regulatory requirements and reflects the company's actual situation without false records or omissions. However, the document itself does not contain the full semi-annual report or detailed financial statements but rather announces the approval and provides links to where the full report can be found. The document length is 2933 characters, which is relatively short and consistent with an announcement rather than the full report. According to the "Menu vs Meal" rule, since this document announces the approval of the semi-annual report and directs readers to the full report elsewhere, it should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR).
2015-08-25 Chinese
关于第四届董事会第二十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the 4th Board of Directors of 嘉事堂药业股份有限公司, including nominations for board members, amendments to the company charter, appointment of a vice president, approval of the 2015 semi-annual report and its summary, and plans for a shareholders meeting. It includes biographies of nominated directors and senior management. The document is not the semi-annual report itself but an announcement of board decisions and related corporate governance matters. The presence of board meeting resolutions, director nominations, and management appointments clearly indicates this is a Board/Management Information filing. The document length (5280 characters) and content confirm it is not a brief announcement or a full financial report but a detailed board meeting resolution announcement.
2015-08-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.